ICUI VS DICE Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

ICUI
10/100

ICUI returned -45.55% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

DICE
100/100

DICE returned 204.71% in the last 12 months. Based on SPY's performance of -8.72%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

ICUI
65/100

5 analysts offer 12-month price targets for ICUI. Together, they have an average target of 190, the most optimistic target put ICUI at 190 within 12-months and the most pessimistic has ICUI at 190.

DICE

"Analyst Price Targets" not found for DICE

Technicals

ICUI
25/100

ICUI receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

DICE
75/100

DICE receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

Earnings

ICUI
41/100

ICUI has missed earnings 3 times in the last 20 quarters.

DICE
53/100

DICE has missed earnings 2 times in the last 20 quarters.

Profit

ICUI
51/100

Out of the last 20 quarters, ICUI has had 13 profitable quarters and has increased their profits year over year on 5 of them.

DICE
10/100

Out of the last 11 quarters, DICE has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ICUI
48/100

ICUI has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

DICE
47/100

DICE has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

All score calculations are broken down here to help you make more informed investing decisions

ICU Medical Inc Summary

Nasdaq / ICUI
Healthcare
Medical - Instruments & Supplies
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

DICE Therapeutics, Inc. Common Stock Summary

Nasdaq / DICE
Healthcare
Biotechnology
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.